Audio episod ini mungkin rosak.
How to fix it?
MENGENAI EPISOD INI
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Bahasa Inggeris
Amerika Syarikat
CARI EPISOD LEPAS
Cari episod lepas bagi FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
EPISOD LAIN DALAM PODCAST INI
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada U.S. Food and Drug Administration, Center for Drug Evaluation and Research, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.
SUNTING
Terima kasih kerana membantu memastikan pangkalan data podcast dalam keadaan terkini.
